Despite a warning from the FDA Adverse Event Reporting System, studies have found that SGLT2 inhibitor use is not associated with an increased risk of AKI. Using a sodium-glucose cotransport 2 (SGLT2) ...

Patients with type 2 diabetes who received sodium-glucose cotransporter-2 inhibitors demonstrated a nearly 50% lower risk for systemic autoimmune rheumatic disease vs. those who received dipeptidyl ...

Use of SGLT2 inhibitors rather than GLP-1 receptor agonists is associated with lower risk of progression to kidney replacement therapy among patients with type 2 diabetes and CKD. The risk of ...

Patients with gout and type 2 diabetes treated with SGLT2 inhibitors not only had reduced numbers of gout flares, but also lived longer compared with other such patients receiving other medications, ...

UBM Medica US announces that Endocrinology Network, a leading online community for endocrinologists and other clinicians who treat patients with T2DM offers comprehensive and up-to-date coverage of ...

Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below: Receive the the latest news, research, and presentations from major meetings ...